Figitumumab

Drug Profile

Figitumumab

Alternative Names: Anti-IGF-1R monoclonal antibody - Pfizer; CP-751,871

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastrointestinal cancer; Gynaecological cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Rheumatoid arthritis; Sarcoma; Small cell lung cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 02 Mar 2011 Discontinued - Phase-I for Multiple myeloma in USA (IV)
  • 28 Feb 2011 Discontinued - Phase-I for Solid tumours in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top